Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research

NASDAQ: ONTX was reduced by  Zacks Research  from a “purchase” rating to a “hold” rating in a research note released to investors on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical company. It concentrates on uncovering as well as creating small molecule medication candidates to treat cancer cells. The Business‘s products under various stages of growth include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous other equities research experts likewise just recently discussed the company. Noble Financial editioned a “buy” score and provided a $11.00 price purpose on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 and set a “get” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and also a twelve month high of $28.95. Business has a 50 day moving typical price of $2.90 as well as a two-hundred day moving typical cost of $4.16. The business has a market cap of $46.76 million, a P/E proportion of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly earnings results on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) earnings per share for the quarter, covering experts’ agreement price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an adverse return on equity of 59.78% as well as a negative web margin of 8,294.27%. The firm had earnings of $0.06 million during the quarter, compared to the agreement price quote of $0.06 million. Throughout the very same quarter in the prior year, the firm posted ($ 0.45) EPS. As a group, research experts forecast that Onconova Therapeutics will post -1.18 EPS for the existing year.

A variety of hedge funds have just recently dealt shares of ONTX. GSA Funding Partners LLP got a brand-new placement in Onconova Therapeutics during the 3rd quarter worth $922,000. Hudson Bay Capital Management LP acquired a brand-new position in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC purchased a brand-new placement in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC got a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP bought a brand-new setting in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds as well as other institutional capitalists possess 13.36% of the company’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which engages in the recognition and development of oncology therapeutics. It focuses on uncovering and developing small molecule medication candidates to treat cancer. The company was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 as well as is headquartered in Newtown, PA

. Get a free duplicate of the Zacks research record on Onconova Therapeutics (ONTX).

For more information concerning research offerings from Zacks Investment Research, browse through Zacks.com.

This instantaneous news alert was generated by narrative science modern technology as well as financial data from Market in order to supply visitors with the fastest and also most precise reporting. This tale was reviewed by Market’s editorial group prior to magazine. 

 

SHOULD YOU SPEND $1,000 IN ONCONOVA THERAPEUTICS RIGHT NOW?

Before you think about Onconova Therapeutics, you’ll wish to hear this.

Market tracks Wall Street’s premier as well as ideal carrying out research experts as well as the stocks they advise to their clients every day. Market has identified the five stocks that top analysts are quietly whispering to their customers to acquire now before the wider market catches on … and Onconova Therapeutics had not been on the listing.

While Onconova Therapeutics presently has a “Buy” score among experts, top-rated experts think these five stocks are much better purchases.